TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In the U.K. SIMPLIFIED trial, 60,000 IU of vitamin D3 every two weeks did not significantly improve overall survival among 3,866 adults receiving dialysis. Researchers also found no significant differences in the listed secondary outcomes; possible subgroup and cardiovascular signals were exploratory and need further study.
A large U.K. trial found that high-dose vitamin D3 did not significantly improve overall survival among adults receiving dialysis for end-stage kidney disease. In the SIMPLIFIED trial, 3,866 participants were assigned to 60,000 IU of cholecalciferol every two weeks or standard care without supplementation, with results presented at the American Society of Nephrology’s Kidney Week meeting.
After a median follow-up of 7.5 years, the researchers found no significant difference in overall survival between the groups. The conditional hazard ratio was 0.95, with a 95% confidence interval of 0.86 to 1.04 and a P value of 0.26. The result does not establish a survival benefit from the high-dose regimen.
The trial also found no significant differences in its reported secondary outcomes: fatal and nonfatal cardiovascular events, infections, fractures and malignancy. A total of 1,817 deaths occurred during the study. Sensitivity analyses that accounted for kidney transplantation, COVID-19 infection and stopping treatment did not change the primary finding.
Vitamin D levels rose substantially in the supplemented group in a check of the first 206 participants: after four months, median 25-hydroxyvitamin D was 141 nmol/L, compared with 36.5 nmol/L in controls. The intervention was described as safe and well tolerated. At least one hospital admission occurred in 69% of the vitamin D group and 70% of the standard-care group.
What the Trial Says About Supplementation
The findings weigh against routinely giving this high-dose vitamin D regimen to dialysis patients for the purpose of improving survival. The trial tested a substantial dose over long-term follow-up and did not detect a significant benefit in its primary outcome. That matters for a population with a high burden of illness and poor long-term outcomes, where vitamin D deficiency is common and observational research has linked low vitamin D levels with worse health outcomes.
The result does not show that vitamin D replacement is never appropriate. It addresses the tested high-dose schedule and the outcomes measured in this trial; it does not settle decisions about treating an individual patient with a documented deficiency. Patients should discuss supplementation and lab results with their kidney-care team rather than changing treatment based on the trial alone.
Researchers reported a nominal reduction in major adverse cardiovascular events, with a hazard ratio of 0.88 (95% CI 0.78-0.99; P=0.03), largely driven by peripheral arterial disease events (HR 0.80, 95% CI 0.65-0.99; P=0.04). These were not confirmed benefits: the study was not powered to establish effects on those individual endpoints, and the overall primary result was null.
Products Worth Considering
Garmin Forerunner 55 GPS Running Smartwatch, Black
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
Oral-B iO Series 5 Rechargeable Electric Toothbrush with Travel Case and 3 Brush Heads, Black
As an affiliate, we earn on qualifying purchases.
Why Researchers Tested Vitamin D
Vitamin D deficiency is common among people receiving dialysis, and observational studies have associated lower levels with mortality and other adverse outcomes. Such associations cannot show that supplementation prevents those outcomes. The trial was designed to address the limited evidence on whether vitamin D replacement improves clinical results in this population.
Kidney Disease: Improving Global Outcomes guidelines suggest measuring 25-hydroxyvitamin D in people with stage 3-5 chronic kidney disease, including those on dialysis, and replacing vitamin D when levels are deficient. Rona Smith of the University of Cambridge said the guidelines acknowledge that the supporting evidence is low-grade. SIMPLIFIED tested a specific high-dose approach, rather than every possible dose or treatment decision.
The pragmatic trial enrolled patients at 55 U.K. renal units. Participants had a median age of 65; 68% were men, 80% were white and 40% had diabetes. Nearly all were receiving in-center hemodialysis, and the median time on dialysis at enrollment was 2.25 years. People with an expected life span under six months, recent use of more than 1,000 IU of cholecalciferol daily, or persistent hypercalcemia were excluded.
How to Read the Subgroup Signals
Prespecified subgroup analyses suggested a possible benefit among men and participants of non-white ethnicity. Smith cautioned that the trial was not powered to establish effects in those groups, so the findings are exploratory rather than definitive. She said lower baseline vitamin D levels among non-white participants could make that subgroup worth studying further, but the trial does not confirm that supplementation improves their survival.
The nominal cardiovascular findings also require caution. The reported reductions in major adverse cardiovascular events and peripheral arterial disease were not powered as definitive endpoint results, and the source report does not establish that they represent a reliable treatment effect. The study’s overall result remained no significant survival improvement.
The findings also do not resolve whether a different dose, duration or approach to replacing a measured deficiency would affect outcomes. The reported comparison was high-dose cholecalciferol every two weeks against standard care without supplementation; it was not a trial of every vitamin D strategy used in kidney care.
Questions for Future Dialysis Studies
Further research could test whether the exploratory signals in men or non-white patients can be reproduced, and whether any benefit is limited to people with particular baseline vitamin D levels. Such studies would need enough participants and follow-up to assess survival and cardiovascular outcomes in those groups directly.
For now, the reported findings offer no basis for routine use of the tested high-dose schedule to improve survival. Clinicians and patients can continue to make supplementation decisions in light of measured vitamin D levels, existing guidance and individual circumstances. The available report does not specify a new guideline change or a planned follow-up study.
Key Questions
Did high-dose vitamin D improve survival in dialysis patients?
No significant improvement was found. In SIMPLIFIED, overall survival did not differ significantly between participants assigned 60,000 IU of cholecalciferol every two weeks and those receiving standard care without supplementation.
How many people took part in the trial?
The trial randomized 3,866 adults receiving dialysis for end-stage kidney disease at 55 U.K. renal units.
Were there any possible benefits in particular groups?
Exploratory analyses suggested possible benefit among men and participants of non-white ethnicity. Researchers said the trial was not powered to confirm subgroup effects, so those observations need further study.
Does the result mean dialysis patients should not take vitamin D?
No. The trial tested a specific high-dose schedule and did not find a significant survival benefit. It does not rule out treating a documented deficiency or address every dose and treatment approach. Patients should discuss vitamin D testing and supplementation with their kidney-care team.
Was the high-dose treatment reported as safe?
The study report described cholecalciferol as safe and well tolerated, and hospital admission rates were similar: 69% in the intervention group and 70% with standard care. These findings do not establish a survival benefit.
Source: medpagetoday.com
